How HPC Enables Drug Design, and AstraZeneca Lessons in HPC

Dell Technologies HPC Community Event

HPC and accelerator-driven computing have become pivotal to drive research in Pharma. Where 5 years ago less than 1% of the researchers actively used HPC resources, AstraZeneca is driving a clear strategy to gain the majority of insights by 2025 through data and AI. This ambition is leading to a constant change in how our researchers work and are presenting an unstoppable appetite for computing.

We will discuss the journey of the last 5 years renewing the approach we are taking towards high-performance computing, explore use cases that are leveraging compute in significantly different ways, driving our research in innovative ways, and share an outlook and vision into our future direction.

To register